Serum free and total prostate-specific antigen levels in patients with liver disease

Urology

Volumn 52, Issue 5, 1998, Pages 825-827

  Kiliç, Sahir ^a   Güntekin, Erol ^a   Danişman, Ahmet ^a   Kukul, Erdal ^a   Süleymanlar, Inci ^a   Sevük, Metin ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ANTIGEN DETECTION; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ASSAY; STATISTICAL ANALYSIS;

EID: 0344863100     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00393-8     Document Type: Article

References (18)

1. Wang M.C., Valenzuela L.A., Murphy G.P., et al. Purification of human prostate-specific antigen. Invest Urol. 17:1979;159-163.
2. Christensson A., Laurel C.B., Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 194:1990;755-763.
3. 1-antichymotrypsin. Clin Chem. 37:1991;1618-1625.
4. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer assay of the complex improves clinical sensitivity for cancer . Cancer Res. 51:1991;222-226.
5. 1-antichymotrypsin as an indicator of prostate cancer. J Urol. 150:1993;100-105.
6. 1-antichymotrypsin. Clin Chem. 39:1993;2098-2103.
7. Catalona W.J., Smith D.S., Wolfert R.L., et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 274:1995;1214-1220.
8. Agha A.H., Schechter E., Roy J.B., et al. Prostate-specific antigen is metabolized in the liver. J Urol. 155:1996;1332-1335.
9. Witherspoon L., Shuler S., Lapeyroleria T. Immulite prostate specific antigen (PSA) assay. Clin Chem. 41:1995;S224.
10. Benson M.C., Whang I.S., Pantluck A., et al. Prostate-specific antigen density a means of distinguishing benign prostatic hyperplasia and prostate cancer . J Urol. 147:1992;815-816.
11. Seeman E., Whang M.S., Ollsson C.A., et al. PSA density (PSAD) role in patient evaluation and management . Urol Clin North Am. 20:1993;653-663.
12. Oesterling J.E., Chute C.G., Jacobsen S.J., et al. Longitudinal changes in serum PSA (PSA velocity) in a community-based cohort of men. J Urol. 149:1993;412A.
13. Oesterling J.E., Jacobsen S.J., Chute C.G., et al. Prostate-specific antigen in a community-based population of healthy men establishment of age-specific ranges . JAMA. 270:1993;860-864.
14. Collins G.N., Lee R.J., McKelvic G.B., et al. Relationship between prostate-specific antigen, prostate volume and age in the benign prostate. Br J Urol. 71:1993;445-450.
15. 1-proteinase inhibitor, antithrombin II and heparin cofactor II. Biochim Biophys Acta. 967:1988;158-162.
16. Travis J., Salvesen G.S. Human plasma proteinase inhibitors. Annu Rev Biochem. 52:1983;655-709.
17. Kadayifci A., Benekli M., Simsek H., et al. Prostatic acid phosphatase and prostate specific antigen in liver disease. Int Urol Nephrol. 28:1996;67-71.
18. Williams P.B., Eastman J.A., Culkin D.J., et al. Influence of hepatic function on serum levels of prostate specific antigen. J Urol. 158:1997;1867-1869.